Maximus: A Discount To Peers, Even If The Recent Contract Change Is Permanent

Maximus cut fiscal 2026 adjusted EPS guidance to $7.90-$8.20 after the VA suspended medical-exam program performance incentives from July 1 through December 31, 2026. Excluding those incentives, adjusted EPS could be about $7 annually, but MMS trades at 6.9x the $8.05 guidance midpoint and 7.9x the estimated no-incentive EPS, below Leidos at 11.5x and Booz Allen at 12x trailing earnings. The company also offers a 15% trailing free-cash-flow yield and the lowest leverage among peers, supporting a valuation-offsetting downside argument.

Analysis

The valuation gap implies the market is discounting more than a temporary earnings interruption: it is pricing either a lower long-run incentive rate, an unfavorable contract reset, or weak cash conversion. The critical distinction is whether the withheld amount remains contractually earned but deferred versus subject to re-performance; the former creates a 1-2 quarter timing issue, while the latter resets the program's normalized margin base. Monitor accounts receivable, contract assets, and operating cash flow at the next two results rather than relying on adjusted EPS.

MMS has unusually concentrated exposure to a single agency decision, so the relevant catalyst is administrative rather than macroeconomic. A resumption, retroactive payment determination, or confirmation that service-level metrics remain intact could drive a rapid multiple normalization over 3-6 months; conversely, extension beyond year-end would make a sub-$7 earnings run-rate the appropriate anchor and likely pressure the shares despite the apparent FCF yield. BAH and LDOS are imperfect valuation comparables because their defense, intelligence, and consulting mixes carry different recompete and budget sensitivities, limiting the usefulness of a pure peer-multiple catch-up thesis.

Consensus may be underweight the possibility that the payment pause improves VA negotiating leverage ahead of future program economics, even if near-term amounts are ultimately paid. The upside case therefore requires evidence of both payment restoration and preservation of incentive mechanics; absent that evidence, the low multiple is compensation for a policy-dependent revenue stream rather than a clear mispricing.

Key Decisions for Investors

• Place MMS on a catalyst watch rather than buying solely on the headline: initiate a 50% long only if the next filing shows stable contract assets/receivables and management confirms the withheld incentives are earned or recoverable. Add on a formal VA payment decision; expected 6-12 month upside is $63-$72 if earnings normalize and the multiple reaches 9x, versus roughly $45-$49 downside if a $7 run-rate is permanently de-rated to 6.5-7x.
• For existing MMS exposure, reduce position sizing until the December 31, 2026 administrative deadline is clarified. A payment-pause extension, revised incentive scorecard, or fiscal-2027 guide below $7.00 should falsify the recovery thesis and trigger an exit rather than averaging down.
• Do not express the view through a mechanical long MMS/short BAH or LDOS pair. The pair embeds unrelated defense-spending, intelligence-budget, and consulting-demand exposures; use MMS as a discrete event-driven position only after verifying cash-flow treatment.
• At the next earnings release, prioritize three data points: VA-program margin commentary, cash from operations relative to net income, and any change in contract renewal/recompete language. Improvement in EPS without corresponding cash realization would not validate the long thesis.